These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 8740122)

  • 1. Experimental immunization against Lyme borreliosis with recombinant Osp proteins: an overview.
    Sadziene A; Barbour AG
    Infection; 1996; 24(2):195-202. PubMed ID: 8740122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lyme disease vaccine.
    Wormser GP
    Infection; 1996; 24(2):203-7. PubMed ID: 8740123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi.
    Golde WT; Burkot TR; Piesman J; Dolan MC; Capiau C; Hauser P; Dequesne G; Lobet Y
    Vaccine; 1995 Apr; 13(5):435-41. PubMed ID: 7639011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes.
    Comstedt P; Schüler W; Meinke A; Lundberg U
    PLoS One; 2017; 12(9):e0184357. PubMed ID: 28863166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody.
    Pal U; Montgomery RR; Lusitani D; Voet P; Weynants V; Malawista SE; Lobet Y; Fikrig E
    J Immunol; 2001 Jun; 166(12):7398-403. PubMed ID: 11390491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
    Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
    BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and development of a novel vaccine for protection against Lyme borreliosis.
    Comstedt P; Hanner M; Schüler W; Meinke A; Lundberg U
    PLoS One; 2014; 9(11):e113294. PubMed ID: 25409015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new approach to a Lyme disease vaccine.
    Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with meningococcal outer membrane vesicles carrying Borrelia OspA protects against experimental Lyme borreliosis.
    Klouwens MJ; Salverda MLM; Trentelman JJ; Ersoz JI; Wagemakers A; Gerritzen MJH; van der Ley PA; Hovius JW
    Vaccine; 2021 Apr; 39(18):2561-2567. PubMed ID: 33812741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination of natural reservoir hosts with recombinant lipidated OspA induces a transmission-blocking immunity against Lyme disease spirochaetes associated with high levels of LA-2 equivalent antibodies.
    Kurtenbach K; Dizij A; Voet P; Hauser P; Simon MM
    Vaccine; 1997 Oct; 15(15):1670-4. PubMed ID: 9364698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of outer surface proteins A and C of Borrelia burgdorferi in Ixodes ricinus ticks removed from humans.
    Fingerle V; Liegl G; Munderloh U; Wilske B
    Med Microbiol Immunol; 1998 Oct; 187(2):121-6. PubMed ID: 9832327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA.
    Fikrig E; Barthold SW; Kantor FS; Flavell RA
    Science; 1990 Oct; 250(4980):553-6. PubMed ID: 2237407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lyme borreliosis in transgenic mice tolerant to Borrelia burgdorferi OspA or B.
    Fikrig E; Tao H; Chen M; Barthold SW; Flavell RA
    J Clin Invest; 1995 Oct; 96(4):1706-14. PubMed ID: 7560061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi.
    Luke CJ; Carner K; Liang X; Barbour AG
    J Infect Dis; 1997 Jan; 175(1):91-7. PubMed ID: 8985201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of recombinant Bacille Calmette-Guérin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine.
    Edelman R; Palmer K; Russ KG; Secrest HP; Becker JA; Bodison SA; Perry JG; Sills AR; Barbour AG; Luke CJ; Hanson MS; Stover CK; Burlein JE; Bansal GP; Connor EM; Koenig S
    Vaccine; 1999 Feb; 17(7-8):904-14. PubMed ID: 10067697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A recombinant vaccine for Lyme disease.
    Wallich R; Kramer MD; Simon MM
    Behring Inst Mitt; 1994 Dec; (95):106-8. PubMed ID: 7755503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abilities of OspA proteins from different seroprotective groups of Borrelia burgdorferi to protect hamsters from infection.
    Lovrich SD; Callister SM; DuChateau BK; Lim LC; Winfrey J; Day SP; Schell RF
    Infect Immun; 1995 Jun; 63(6):2113-9. PubMed ID: 7768589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune sera to individual Borrelia burgdorferi isolates or recombinant OspA thereof protect SCID mice against infection with homologous strains but only partially or not at all against those of different OspA/OspB genotype.
    Schaible UE; Wallich R; Kramer MD; Gern L; Anderson JF; Museteanu C; Simon MM
    Vaccine; 1993; 11(10):1049-54. PubMed ID: 8212826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of protection in rabbits against host-adapted and cultivated Borrelia burgdorferi following infection-derived immunity or immunization with outer membrane vesicles or outer surface protein A.
    Shang ES; Champion CI; Wu XY; Skare JT; Blanco DR; Miller JN; Lovett MA
    Infect Immun; 2000 Jul; 68(7):4189-99. PubMed ID: 10858236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine.
    Stover CK; Bansal GP; Hanson MS; Burlein JE; Palaszynski SR; Young JF; Koenig S; Young DB; Sadziene A; Barbour AG
    J Exp Med; 1993 Jul; 178(1):197-209. PubMed ID: 8315378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.